Clinicopathologic characteristics of pancreatic neuroendocrine tumors and relation of somatostatin receptor type 2A to outcomes

Expression of Somatostatin Receptor (SSTR) Subtypes (SSTR-1, 2A, 3, 4 and 5) in Neuroendocrine Tumors Using Real-time RT-PCR Method and Immunohistochemistry

(2012) Gou Mizutani et al.   ACTA HISTOCHEMICA ET CYTOCHEMICA

Comparison of Chemotherapeutic Treatment Outcomes of Advanced Extrapulmonary Neuroendocrine Carcinomas and Advanced Small-Cell Lung Carcinoma

(2012) T. Terashima et al.   NEUROENDOCRINOLOGY

Ki-67 predicts disease recurrence and poor prognosis in pancreatic neuroendocrine neoplasms

(2012) Nicholas A. Hamilton et al.   SURGERY

Monoclonal Antibodies against the Human Somatostatin Receptor Subtypes 1–5: Development and Immunohistochemical Application in Neuroendocrine Tumors

(2011) Herbert A. Schmid et al.   NEUROENDOCRINOLOGY

Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors

(2011) Eric Raymond et al.   NEW ENGLAND JOURNAL OF MEDICINE

Everolimus for Advanced Pancreatic Neuroendocrine Tumors

(2011) James C. Yao et al.   NEW ENGLAND JOURNAL OF MEDICINE

Role of Somatostatins in Gastroenteropancreatic Neuroendocrine Tumor Development and Therapy

(2010) Kjell E. Öberg et al.   GASTROENTEROLOGY

Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan

(2010) Tetsuhide Ito et al.   JOURNAL OF GASTROENTEROLOGY

Somatostatin Receptor Subtypes 2 and 5 Are Associated with Better Survival in Well-Differentiated Endocrine Carcinomas

(2008) Vito D. Corleto et al.   NEUROENDOCRINOLOGY